Tom Jayram, MD, breaks down some of the most significant advancements in kidney cancer diagnosis and care from the LUGPA 2024 Annual Meeting. Dr. Jayram discusses the potential of girentuximab PET to revolutionize kidney cancer care, drawing parallels to the rise of PSMA in prostate cancer. Dr. Jayram also highlights the importance of adjuvant pembrolizumab for high-risk kidney cancer patients post-nephrectomy, emphasizing its demonstrated overall survival benefits.
0:17 The Impact of Girentuximab PET on Kidney Cancer
1:16 Adjuvant Pembrolizumab for High-Risk Kidney Cancer
1:49 Biomarker Research in Kidney Cancer
2:13 Girentuximab PET Uptake as a Potential Biomarker
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.